Imugene Limited
IUGNF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | -$0 | $0 |
| % Growth | 149.5% | 140.6% | -138.4% | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -602.3% | -3,857.1% | 2,495.3% | -857.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -659% | -3,842.5% | 2,613.5% | -851.7% |
| EPS Diluted | -0.094 | -0.22 | -0.38 | -0.34 |
| % Growth | 57.2% | 42.1% | -11.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |